Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Heuser

Showing results (261-270 of 280) with videos related to

Pageof 28
Sort By:
Blood|December 28, 2020
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trialSilke Kapp-Schwoerer, Daniela Weber, Andrea Corbacioglu, et al.
The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Blood Cancer Discovery|July 15, 2022
Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid LeukemiaJune Takeda, Kenichi Yoshida, Masahiro M Nakagawa, et al.
Blood Advances|October 13, 2020
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trialMaria Teresa Voso, Richard A Larson, Dan Jones, et al.
Blood|April 30, 2020
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSLuca Malcovati, Kristen Stevenson, Elli Papaemmanuil, et al.
Blood|December 12, 2019
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemiaKonstanze Döhner, Christian Thiede, Nikolaus Jahn, et al.
Blood Cancer Journal|October 5, 2021
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Friedrich Stölzel, Christoph Röllig, et al.
Blood Cancer Journal|April 8, 2025
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patientsChristina Rautenberg, Jan Moritz Middeke, Christoph Röllig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk ModelCurtis A Lachowiez, Joshua F Zeidner, Jad Othman, et al.
Leukemia|January 13, 2019
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroupsDetlef Haase, Kristen E Stevenson, Donna Neuberg, et al.
Pageof 28

Showing results (261-270 of 280) with videos related to

Sort By:
Pageof 28
Blood|December 28, 2020
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trialSilke Kapp-Schwoerer, Daniela Weber, Andrea Corbacioglu, et al.
The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Blood Cancer Discovery|July 15, 2022
Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid LeukemiaJune Takeda, Kenichi Yoshida, Masahiro M Nakagawa, et al.
Blood Advances|October 13, 2020
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trialMaria Teresa Voso, Richard A Larson, Dan Jones, et al.
Blood|April 30, 2020
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSLuca Malcovati, Kristen Stevenson, Elli Papaemmanuil, et al.
Blood|December 12, 2019
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemiaKonstanze Döhner, Christian Thiede, Nikolaus Jahn, et al.
Blood Cancer Journal|October 5, 2021
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Friedrich Stölzel, Christoph Röllig, et al.
Blood Cancer Journal|April 8, 2025
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patientsChristina Rautenberg, Jan Moritz Middeke, Christoph Röllig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk ModelCurtis A Lachowiez, Joshua F Zeidner, Jad Othman, et al.
Leukemia|January 13, 2019
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroupsDetlef Haase, Kristen E Stevenson, Donna Neuberg, et al.
Pageof 28